Hcc 70

The human breast cancer cell lines BT-549, HS578T, MDA-MB-231, MDA-MB-468, T47D, and MCF-7 were obtained from the National Cancer Institute (NCI, USA). One human breast cancer cell line (HCC-70) was obtained from the Korean Cell Line Bank (KCLB, Seoul, Korea). MDA-MB-231 and MCF-7 human breast cancer cell lines were maintained in DMEM/HIGH GLUCOSE (HyClone, Marlborough, MA, USA) with 10% fetal bovine serum (FBS, HyClone) supplemented with 1% penicillin–streptomycin (Welgene, Daegu, Republic of Korea) and MycoZap (Lonza, Basel, Switzerland). BT-549, HS578T, MDA-MB-468, T47D, and HCC-70 human breast cancer cell lines were maintained in RPMI-1640 medium (HyClone) supplemented with 10% FBS (HyClone) supplemented with 1% penicillin–streptomycin (Welgene) and MycoZap (Lonza). All breast cancer cell lines were cultured in a 5% CO₂ incubator at 37 °C. A stable MCF-7 cell line overexpressing AXL was produced via puromycin selection. Human umbilical vein endothelial cells (HUVECs; Lonza and Yale VBT Core, New Haven, CT, USA) were cultured in a 5% CO₂ incubator at 37 °C with EBM-2 basal medium supplemented with EGM-2 (Lonza) with 1% penicillin–streptomycin (Welgene). HUVECs (passages 3–7) were grown to 70% to 90% confluence.

The breast cancer cell lines used were MDA-MB-231, MDA-MB-453, HCC70, BT-20, and Hs578T cells, which were purchased from the Korean Cell Line Bank (Seoul, Republic of Korea), and BT-549 cells, which were purchased from ATCC (Manassas, VA, USA). The cells were grown in a humidified atmosphere with 5% CO₂ at 37 °C in either Dulbecco’s Modified Eagle Medium (DMEM) or RPMI Medium 1640 (RPMI), supplemented with 10% FBS and penicillin.